Multi-Institutional Assessments of Transplantation for Metabolic Disorders

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1 SUPPL., 2013, Pages

  Orchard, Paul ^a   Boelens, Jaap Jan ^b   Raymond, Gerald ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOLEUKODYSTROPHY; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ENZYME ACTIVITY; ENZYME REPLACEMENT; EVENT FREE SURVIVAL; GRAFT FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HURLER SYNDROME; METABOLIC DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TRANSPLANTATION;

FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; METABOLISM, INBORN ERRORS; MULTICENTER STUDIES AS TOPIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 84871875870     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.10.026     Document Type: Article

References (32)

1. Fratantoni J.C., Hall C.W., Neufeld E.F. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 1968, 162:570-572.
2. Hobbs J.R., Hugh-Jones K., Barrett A.J., et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 1981, 2:709-712.
3. Kakkis E.D., Schuchman E., He X., et al. Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol Genet Metab 2001, 72:199-208.
4. Wraith J.E. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 2005, 6:489-506.
5. Boelens J.J., Wynn R.F., O'Meara A., et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant 2007, 40:225-233.
6. Martin P.L., Carter S.L., Kernan N.A., et al. Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol Blood Marrow Transplant 2006, 12:184-194.
7. Prasad V.K., Mendizabal A., Parikh S.H., et al. Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. Blood 2008, 112:2979-2989.
8. Staba S.L., Escolar M.L., Poe M., et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 2004, 350:1960-1969.
9. Aldenhoven M., Boelens J.J., de Koning T.J. The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:485-498.
10. Boelens J., Aldenhoven M., Purtill D., et al. Outcomes of transplantation using a various cell source in children with hurlers syndrome after myelo-ablative conditioning. An Eurocord-EBMT-CIBMTR collaborative study. Biol Blood Marrow Transplant 2010, 16(Suppl 2):S180-S181.
11. Chen N., Hudson J.E., Walczak P., et al. Human umbilical cord blood progenitors: the potential of these hematopoietic cells to become neural. Stem Cells 2005, 23:1560-1570.
12. Kogler G., Sensken S., Airey J.A., et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004, 200:123-135.
13. Aldenhoven M., Sakkers R.J., Boelens J., et al. Musculoskeletal manifestations of lysosomal storage disorders. Ann Rheum Dis 2009, 68:1659-1665.
14. Manger B., Mengel E., Schaefer R.M. Rheumatologic aspects of lysosomal storage diseases. Clin Rheumatol 2007, 26:335-341.
15. Igarashi M., Schaumburg H.H., Powers J., et al. Fatty acid abnormality in adrenoleukodystrophy. J Neurochem 1976, 26:851-860.
16. Bezman L., Moser A.B., Raymond G.V., et al. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol 2001, 49:512-517.
17. Mahmood A., Dubey P., Moser H.W., Moser A. X-linked adrenoleukodystrophy: Therapeutic approaches to distinct phenotypes. Pediatr Transplant 2005, 9:55-62.
18. Powers J.M., Pei Z., Heinzer A.K., et al. Adrenoleukodystrophy: oxidative stress of mice and men. J Neuropathol Exp Neurol 2005, 64:1067-1079.
19. Aubourg P., Blanche S., Jambaque I., et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 1990, 322:1860-1866.
20. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326:818-823.
21. Miller W.P., Rothman S.M., Nascene D., et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood 2011, 118:1971-1978.
22. Peters C., Charnas L.R., Tan Y., et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 2004, 104:881-888.
23. Loes D.J., Fatemi A., Melhem E.R., et al. Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology 2003, 61:369-374.
24. Loes D.J., Stillman A.E., Hite S., et al. Childhood cerebral form of adrenoleukodystrophy: short-term effect of bone marrow transplantation on brain MR observations. AJNR Am J Neuroradiol 1994, 15:1767-1771.
25. Moser H.W., Fatemi A., Zackowski K., et al. Evaluation of therapy of X-linked adrenoleukodystrophy. Neurochem Res 2004, 29:1003-1016.
26. Moser H.W., Mahmood A., Raymond G.V. X-linked adrenoleukodystrophy. Nat Clin Pract Neurol 2007, 3:140-151.
27. Chen A., Vogler C., McEntee M., et al. Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase. APMIS Acta Pathol Microbiol Immunol Scand 2011, 119:513-521.
28. Orchard P.J., Lund T., Miller W., et al. Chitotriosidase as a biomarker of cerebral adrenoleukodystrophy. J Neuroinflamm 2011, 8:144.
29. Moser H.W., Loes D.J., Melhem E.R., et al. X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients. Neuropediatrics 2000, 31:227-239.
30. van Geel B.M., Bezman L., Loes D.J., et al. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol 2001, 49:186-194.
31. Loes D.J., Hite S., Moser H., et al. Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol 1994, 15:1761-1766.
32. Moser H.W., Bezman L., Lu S.E., Raymond G.V. Therapy of X-linked adrenoleukodystrophy: prognosis based upon age and MRI abnormality and plans for placebo-controlled trials. J Inherit Metab Dis 2000, 23:273-277.